LINKOPING, Sweden, Dec. 2, 2020 /PRNewswire/
-- International medical imaging IT and cybersecurity
company Sectra (STO: SECT B) has signed a distribution
agreement with RSA Biomedical. Under the contract, RSA Biomedical
will now offer Sectra CT-based Micromotion Analysis (Sectra CTMA®).
This measurement method facilitates time and cost-efficient
clinical validation of orthopaedic implant movement for the benefit
of patient safety.
"For the past two decades, we have supported orthopaedists and
implant manufacturers by providing measurement methods for
validating implants and our brand is market leading in terms of
quality. Sectra's CT-based measurement method represents a paradigm
shift in this field as it contains clear advantages for patients,
surgeons and the implant industry. We are excited about the
opportunity to help bring this emerging technology to the market,"
says Per Grundström, President and CEO of RSA Biomedical.
RSA Biomedical is a worldwide provider of high-precision
products and measurement systems in digital medical imaging.
Hundreds of hospitals, clinicians, medical researchers, and medical
device manufacturers in North
Australia, and Asia use the RSA method.
"RSA Biomedical clearly understands what is needed to bring an
orthopaedic implant into clinical practice. Its support of the move
toward CT-based measurements represents an important step forward
in efforts to make this type of validation the new gold standard.
I'm excited about what our collaboration will lead to in terms of
increased availability of safer orthopaedic implants and
ultimately, improved patient outcomes," says Gustaf Schwang, General Manager Business Unit
Orthopaedic Solutions at Sectra.
About Sectra CTMA
Sectra CTMA is a method that facilitates the measurement of
movements between implants and bone using computed tomography
images (CT images). The method uses CT images taken typically up to
two years after implantation to measure the 3D movement of an
implant or bone fragment on a submillimeter scale. With this data,
scientists can analyze the movement of an implant or bone segment
over time. This early high-precision information provides a strong
predictor of the long-term survival of the implant.
Sectra CTMA is part of the orthopaedic module of Sectra's
enterprise imaging solution. The enterprise imaging solution
provides a unified strategy for all imaging needs while lowering
operational costs. The scalable and modular solution, with a VNA at
its core, allows healthcare providers to grow from ology to ology
and from enterprise to enterprise. Read more about Sectra's
enterprise imaging solution and why Sectra PACS is ranked "Best in
KLAS" for seven consecutive years at medical.sectra.com.
Sectra CTMA is a registered trademark of Sectra AB and is patent
Sectra assists hospitals throughout the world to enhance the
efficiency of care, and authorities and defense forces in
Europe to protect society's most
sensitive information. Thereby, Sectra contributes to a healthier
and safer society. The company was founded in 1978, has its head
office in Linköping, Sweden, with
direct sales in 19 countries, and operates through partners
worldwide. Sales in the 2019/2020 fiscal year totaled SEK 1,661 million. The Sectra share is quoted on
the Nasdaq Stockholm exchange. For more information, visit
For further information, please contact:
Dr. Torbjörn Kronander CEO and President Sectra AB, +46 (0)
705 23 52 27
Gustaf Schwang, General Manager
of Business Unit Orthopeadics at Sectra, +46 (0) 734 16 08
This information was brought to you by Cision
The following files are available for download: